Tech Company Financing Transactions

Oak Hill Bio Funding Round

Oak Hill Bio closed a $32.5 million Series A funding round on 6/1/2026. Investors included Balyasny Asset Management, Janus Henderson Investors and venBio.

Transaction Overview

Company Name
Oak Hill Bio
Announced On
6/1/2026
Transaction Type
Venture Equity
Amount
$32,500,000
Round
Series A
Investors

Balyasny Asset Management (Lead Investor)

Janus Henderson Investors (Lead Investor)

venBio (Lead Investor) (Rich Gaster)

Proceeds Purpose
Proceeds from the financing will be used to advance rugonersen, an investigational ASO therapy for the treatment of Angelman syndrome, into a pivotal Phase 3 clinical study.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3rd Floor, 1 Ashley Road
Altrincham, Cheshire, WA14 2DT
UK
Phone
Undisclosed
Website
www.oakhillbioholdings.com
Email Address
[email protected]
Overview
Oak Hill Bio Holdings Ltd (formerly known as Oak Hill Bio Ltd) was founded in 2021 to acquire and develop outstanding rare disease therapeutics deprioritized by big pharma. Oak Hill Bio Holdings is developing OHB-607, a replacement therapy designed to prevent complications of prematurity in extremely preterm infants. OHB-607 is currently in a phase 2b study.
Profile
Oak Hill Bio LinkedIn Company Profile
Social Media
Oak Hill Bio Company Twitter Account
Company News
Oak Hill Bio News
Facebook
Oak Hill Bio on Facebook
YouTube
Oak Hill Bio on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Josh Distler
  Josh Distler LinkedIn Profile  Josh Distler Twitter Account  Josh Distler News  Josh Distler on Facebook
Chief Medical Officer
Victoria Niklas
  Victoria Niklas LinkedIn Profile  Victoria Niklas Twitter Account  Victoria Niklas News  Victoria Niklas on Facebook
Chief Operating Officer
Sharon Morriss
  Sharon Morriss LinkedIn Profile  Sharon Morriss Twitter Account  Sharon Morriss News  Sharon Morriss on Facebook
Chief Scientific Officer
Mark McHale
  Mark McHale LinkedIn Profile  Mark McHale Twitter Account  Mark McHale News  Mark McHale on Facebook
VP - Bus. Development
Ike Greenstein
  Ike Greenstein LinkedIn Profile  Ike Greenstein Twitter Account  Ike Greenstein News  Ike Greenstein on Facebook

 

 

Browse more venture capital transactions:

Prev: 6/1/2026: Veritas Aortic Solutions venture capital transaction
Next: 6/1/2026: Xavveo venture capital transaction

 

Share this article

 

Where The Data Comes From

Our team works diligently to report on tech company VC transactions. VC transactions reported here are derived from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2026. Gaebler Ventures. All rights reserved.